14. March 2017
Traditional sterilization methods, such as ethylene oxide (EO), gamma radiation can leave behind dangerous carcinogenic residuals or even damage and degrade a product’s materials or packaging. REVOX has developed a room-temperature sterilization process that uses Vaporized Peracetic Acid (VPA) to gently sterilize all surfaces of a product within its package. This patented technology has excellent penetration capabilities, and leaves behind no residuals. VPA breaks down into relatively...
13. March 2017
Grace will present a detailed discussion of the mechanisms of silica for solubility enhancement for BCS class II drugs. We will introduce effective methods of particle engineering of compendial silicon dioxide to create stable amorphous dispersions.Specific discussion will include: Case studies demonstrating technology efficacy Practical considerations for scale up and formulation development Benefits of this technology for transfer to clinical trials Additionally, Grace will demonstrate the...
12. March 2017
AFFINISOL™ polymers are uniquely tailored to address solubilization performance requirements. Several case studies will be presented: AFFINISOL™ for Spray Dried Dispersions HPMCAS products with a broad range of release propertiesCreating an amorphous dispersion via top spray-granulation AFFINISOL™ HPMC for Hot Melt Extrusion New cellulosic materials maintaining the crystallization inhibiting properties of traditional HPMC, but can be extruded over a wide temperature range without the use...
11. March 2017
Several nanoparticulate drug products joined the market in the last decade with commercial success. More recently, generic copies of originator products joined also the market demonstrating attractive and promising business areas. However, strategic drawbacks and technical limitations are nonetheless obvious to extract the inherent capabilities of nanosuspension based drug products. For instance: When should be a nanosuspension approach selected for a poorly soluble compound? Do we have...